Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
arcticnovartis
Fri, 03/20/2026 – 07:04
Read more about Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its…
